GOODMAN AND GILMAN'S THE
PHARMACOLOGICAL BASIS OF
THERAPEUTICS
14TH EDITION
• AUTHOR(S)LAURENCE BRUNTON;
BJORN KNOLLMANN
TEST BANK
1
Reference
Ch. 1 — Natural Products & Lead Identification
Stem
A 68-year-old patient with metastatic cancer is prescribed a
newly discovered alkaloid derivative that originated from a
rainforest plant. As a translational pharmacologist evaluating
the compound for further development, you must prioritize
features predicting clinical success beyond in-vitro potency.
,Which property most strongly predicts early failure during
preclinical to clinical transition?
Options
A. High in-vitro potency (nanomolar IC₅₀) at the target receptor
B. Poor aqueous solubility and low bioavailability in animal
models
C. Unique chemical scaffold distinct from marketed drugs
D. Strong activity in a cell-based phenotypic assay
Correct answer
B
Rationale — Correct (B)
Poor aqueous solubility and low bioavailability commonly
prevent sufficient systemic exposure in vivo, causing lead
compounds to fail despite promising in-vitro potency. ADME
limitations (absorption/distribution/metabolism/excretion) are
frequent causes of attrition during the preclinical → clinical
translation phase and require optimization or prodrug
strategies.
Rationales — Incorrect
A. High in-vitro potency is necessary but not sufficient; many
potent molecules fail due to ADME/toxicity.
C. A novel scaffold is valuable for IP and novelty but does not
ensure drug-like properties or safety.
D. Phenotypic activity is predictive of functional effects but,
without acceptable pharmacokinetics, clinical translation
remains unlikely.
,Teaching point
ADME properties (solubility, permeability, clearance) often drive
early drug failure more than in-vitro potency.
Citation
Brunton, L. L., & Knollmann, B. C. (2023). Goodman & Gilman’s
The Pharmacological Basis of Therapeutics (14th ed.). Ch. 1.
2
Reference
Ch. 1 — Target Validation & Genetic Evidence
Stem
A 52-year-old man with familial hypercholesterolemia has a
loss-of-function variant in gene X associated epidemiologically
with reduced atherosclerotic events. As a pharmacologist
selecting targets, you must evaluate genetic validation. Which
conclusion best supports prioritizing gene X for small-molecule
inhibition?
Options
A. Loss-of-function variants in gene X increase coronary risk in
animal models.
B. Human heterozygous carriers of gene X loss-of-function have
lower LDL and fewer cardiovascular events.
C. Gene X is highly conserved across species with unknown
function.
, D. Overexpression of gene X in tumor cell lines increases
proliferation.
Correct answer
B
Rationale — Correct (B)
Human genetic loss-of-function associated with reduced LDL
and fewer events provides strong human genetic validation that
inhibiting gene X could be therapeutic and safe, lowering
translational risk. Human Mendelian or common-variant
evidence is among the most persuasive target validation data.
Rationales — Incorrect
A. Increased risk in animal models argues against inhibition and
may not translate to humans.
C. Conservation alone defines essentiality or complexity but
gives little directional therapeutic guidance.
D. Overexpression in tumors is context-specific and unrelated to
cardiovascular benefit; it does not validate inhibition for lipid
lowering.
Teaching point
Human genetic loss-of-function that correlates with disease
protection is high-value target validation.
Citation
Brunton, L. L., & Knollmann, B. C. (2023). Goodman & Gilman’s
The Pharmacological Basis of Therapeutics (14th ed.). Ch. 1.
PHARMACOLOGICAL BASIS OF
THERAPEUTICS
14TH EDITION
• AUTHOR(S)LAURENCE BRUNTON;
BJORN KNOLLMANN
TEST BANK
1
Reference
Ch. 1 — Natural Products & Lead Identification
Stem
A 68-year-old patient with metastatic cancer is prescribed a
newly discovered alkaloid derivative that originated from a
rainforest plant. As a translational pharmacologist evaluating
the compound for further development, you must prioritize
features predicting clinical success beyond in-vitro potency.
,Which property most strongly predicts early failure during
preclinical to clinical transition?
Options
A. High in-vitro potency (nanomolar IC₅₀) at the target receptor
B. Poor aqueous solubility and low bioavailability in animal
models
C. Unique chemical scaffold distinct from marketed drugs
D. Strong activity in a cell-based phenotypic assay
Correct answer
B
Rationale — Correct (B)
Poor aqueous solubility and low bioavailability commonly
prevent sufficient systemic exposure in vivo, causing lead
compounds to fail despite promising in-vitro potency. ADME
limitations (absorption/distribution/metabolism/excretion) are
frequent causes of attrition during the preclinical → clinical
translation phase and require optimization or prodrug
strategies.
Rationales — Incorrect
A. High in-vitro potency is necessary but not sufficient; many
potent molecules fail due to ADME/toxicity.
C. A novel scaffold is valuable for IP and novelty but does not
ensure drug-like properties or safety.
D. Phenotypic activity is predictive of functional effects but,
without acceptable pharmacokinetics, clinical translation
remains unlikely.
,Teaching point
ADME properties (solubility, permeability, clearance) often drive
early drug failure more than in-vitro potency.
Citation
Brunton, L. L., & Knollmann, B. C. (2023). Goodman & Gilman’s
The Pharmacological Basis of Therapeutics (14th ed.). Ch. 1.
2
Reference
Ch. 1 — Target Validation & Genetic Evidence
Stem
A 52-year-old man with familial hypercholesterolemia has a
loss-of-function variant in gene X associated epidemiologically
with reduced atherosclerotic events. As a pharmacologist
selecting targets, you must evaluate genetic validation. Which
conclusion best supports prioritizing gene X for small-molecule
inhibition?
Options
A. Loss-of-function variants in gene X increase coronary risk in
animal models.
B. Human heterozygous carriers of gene X loss-of-function have
lower LDL and fewer cardiovascular events.
C. Gene X is highly conserved across species with unknown
function.
, D. Overexpression of gene X in tumor cell lines increases
proliferation.
Correct answer
B
Rationale — Correct (B)
Human genetic loss-of-function associated with reduced LDL
and fewer events provides strong human genetic validation that
inhibiting gene X could be therapeutic and safe, lowering
translational risk. Human Mendelian or common-variant
evidence is among the most persuasive target validation data.
Rationales — Incorrect
A. Increased risk in animal models argues against inhibition and
may not translate to humans.
C. Conservation alone defines essentiality or complexity but
gives little directional therapeutic guidance.
D. Overexpression in tumors is context-specific and unrelated to
cardiovascular benefit; it does not validate inhibition for lipid
lowering.
Teaching point
Human genetic loss-of-function that correlates with disease
protection is high-value target validation.
Citation
Brunton, L. L., & Knollmann, B. C. (2023). Goodman & Gilman’s
The Pharmacological Basis of Therapeutics (14th ed.). Ch. 1.
